Nurix Therapeutics, Inc. (NASDAQ:NRIX – Get Rating) has been assigned an average recommendation of “Buy” from the seven ratings firms that are covering the stock, MarketBeat reports. Five analysts have rated the stock with a buy rating. The average 12-month price target among brokerages that have issued a report on the stock in the last year is $43.14.
Several research firms recently issued reports on NRIX. HC Wainwright lowered their price objective on Nurix Therapeutics from $62.00 to $60.00 and set a “buy” rating on the stock in a research report on Thursday, April 14th. Piper Sandler reduced their price objective on Nurix Therapeutics from $55.00 to $35.00 in a research note on Tuesday, May 31st. Needham & Company LLC lowered their target price on Nurix Therapeutics from $48.00 to $38.00 and set a “buy” rating on the stock in a research report on Friday, May 27th. Royal Bank of Canada decreased their price objective on Nurix Therapeutics from $42.00 to $39.00 and set an “outperform” rating on the stock in a research note on Monday, April 18th. Finally, Wells Fargo & Company raised Nurix Therapeutics from an “equal weight” rating to an “overweight” rating and set a $25.00 price objective on the stock in a research report on Tuesday, May 31st.
NRIX stock opened at $12.46 on Thursday. The stock has a market capitalization of $560.08 million, a PE ratio of -4.09 and a beta of 2.60. Nurix Therapeutics has a 12-month low of $7.52 and a 12-month high of $37.42. The stock’s 50 day simple moving average is $10.75 and its 200 day simple moving average is $16.64.
Hedge funds and other institutional investors have recently made changes to their positions in the business. Ensign Peak Advisors Inc increased its stake in Nurix Therapeutics by 512.0% in the 4th quarter. Ensign Peak Advisors Inc now owns 4,890 shares of the company’s stock worth $142,000 after acquiring an additional 4,091 shares during the last quarter. Dimensional Fund Advisors LP bought a new stake in Nurix Therapeutics in the fourth quarter worth $3,369,000. Handelsbanken Fonder AB purchased a new stake in Nurix Therapeutics during the fourth quarter valued at $220,000. ARK Investment Management LLC bought a new position in Nurix Therapeutics during the fourth quarter valued at $1,272,000. Finally, State Board of Administration of Florida Retirement System grew its stake in shares of Nurix Therapeutics by 18.0% in the 4th quarter. State Board of Administration of Florida Retirement System now owns 8,031 shares of the company’s stock worth $232,000 after buying an additional 1,223 shares in the last quarter. Institutional investors own 89.94% of the company’s stock.
Nurix Therapeutics Company Profile (Get Rating)
Nurix Therapeutics, Inc, a biopharmaceutical company, focuses on the discovery, development, and commercialization of small molecule therapies for the treatment of cancer and immune disorders. The company develops NX-2127, an orally available Bruton's tyrosine kinase (BTK) degrader for the treatment of relapsed or refractory B-cell malignancies; NX-5948, an orally bioavailable BTK degrader for the treatment of relapsed or refractory B-cell malignancies and autoimmune diseases; and NX-1607, an orally available Casitas B-lineage lymphoma proto-oncogene-B (CBL-B) inhibitor for immuno-oncology indications.
See Also
- Get a free copy of the StockNews.com research report on Nurix Therapeutics (NRIX)
- Victoria’s Secret Stock is Out of the Box
- Downturn Gives These 3 Buys Juicy Dividend Yields
- Time For a Ride in Six Flags Stock
- Why Dollar General (NYSE: DG) Should Be In Your Portfolio
- Korn Ferry Is A Good Buy For The Recession And Beyond
Receive News & Ratings for Nurix Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Nurix Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.